Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that. Regeneron and Sanofi (NYSE: SNY) reported updated data for cemiplimab in skin cancer earlier today and based on that data, the two companies have begun a rolling application for FDA approval. Will this drug move the needle for these companies?

Cemiplimab belongs to a class of drugs called PD-1 inhibitors that help disable a cancer's ability to escape detection by the immune system.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com